Product logins

Find logins to all Clarivate products below.


Dr Dilpreet Singh, MD Ortho

Partner & Head JAPAC Consulting, Clarivate Consulting Services

Dr. Dilpreet Singh, is an experienced life sciences consultant with over 20 years in pharma & biotech. A surgeon turned management consultant turned entrepreneur and back to consulting, he has breadth of experience across the pharma & life sciences segments including operations & strategy execution.

Dilpreet was a Sr. Principal at L.E.K. Consulting and IQVIA (earlier IMS Health), leading the consulting practice across the SEA and APAC region. He has been a trusted advisor to clients across Market access & Go-to-market strategies, product and portfolio lifecycle management from R&D investments to licensing or launch, along with corporate strategies such as M&A, divestment and partnerships. He also has industry experience, most recently at Cerecin, being the COO of the neuro focused biotech with P3 asset in Alzheimer’s Disease and also at Johnson & Johnson earlier.

He has also been a speaker at industry leading events (eg APACMed, ESMO Asia etc), with published thought leadership across new and emerging technologies, and commercial models in biopharma and medical devices space

Dilpreet is passionate about technology in life sciences and founded Juvoxa, a health-tech patient-centric care platform to drive evidence driven outcomes in specialty care. He is actively involved in startup ecosystem in the region, and is an active investor, mentor and advisor to some promising early-stage startups in the region as well.

Dilpreet holds an MBA from the Indian School of Business, Hyderabad and Masters in Surgery (Orthopedics) from All India Institute of Medical Sciences, Delhi

Latest news

News September 22, 2026
Clarivate to Report Third Quarter 2026 Results on November 3, 2026

London, U.K., September 22, 2026 – (PR Newswire) – Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced it will report its financial results for the third…

News September 17, 2026
Clarivate Commences Offer to Purchase for Cash Certain of its Outstanding Debt Securities

LONDON, September 17, 2026: Clarivate Plc (NYSE: CLVT) (“Clarivate”), a leading global provider of transformative intelligence, today announced that its wholly-owned subsidiary, Clarivate Science Holdings Corporation (the “Company”), has commenced a…

News September 17, 2026
Clarivate Reveals Citation Laureates 2026 Recognizing Transformative Scientific Breakthroughs

22 researchers honored for Nobel-class discoveries, including pioneers of GLP-1 medicines and other world-changing advances London, U.K. September 17, 2026: Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence,…

Related resources

Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval
Blog June 24, 2026
Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval
ADC Biopharma Biotech Bispecific antibodies BsAb Clinical trials Development Oncology Pharma R&D Regulatory Research
Using AI-powered translational safety intelligence to anticipate drug safety issues earlier Using AI-powered translational safety intelligence to anticipate drug safety issues earlier
Blog June 22, 2026
Using AI-powered translational safety intelligence to anticipate drug safety issues earlier
Biopharma Biotech Clinical trials CMC Development R&D Real-World Data Regulatory Research Safety
Three uncomfortable truths about cell and gene therapy in regulatory affairs Three uncomfortable truths about cell and gene therapy in regulatory affairs
Blog May 28, 2026
Three uncomfortable truths about cell and gene therapy in regulatory affairs
Consulting Resource Center Regulatory
How the Inflation Reduction Act could impact access to more convenient therapeutics How the Inflation Reduction Act could impact access to more convenient therapeutics
Blog February 17, 2026
How the Inflation Reduction Act could impact access to more convenient therapeutics
Biopharma Biotech Commercialization Consulting Resource Center FDA HMO Insurance Launch Managed care Market Access North America Payer Pharma pricing Route of administration U.S.